This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alector (ALEC) Surges: Stock Moves 6.9% Higher
by Zacks Equity Research
Alector (ALEC) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Alector (ALEC) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Alector (ALEC) delivered earnings and revenue surprises of -11.54% and -64.12%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Alector (ALEC) delivered earnings and revenue surprises of -10.42% and -32.35%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics (FATE) Looks Good: Stock Adds 8.9% in Session
by Zacks Equity Research
Fate Therapeutics (FATE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Is Alector (ALEC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ALEC) Outperforming Other Medical Stocks This Year?
Alector (ALEC) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Alector (ALEC) delivered earnings and revenue surprises of -2.27% and -37.49%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Alector (ALEC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Alector (ALEC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes Alector (ALEC) a New Buy Stock
by Zacks Equity Research
Alector (ALEC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Alector (ALEC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ALEC) Outperforming Other Medical Stocks This Year?
Are Options Traders Betting on a Big Move in Alector (ALEC) Stock?
by Zacks Equity Research
Investors need to pay close attention to Alector (ALEC) stock based on the movements in the options market lately.
Is Earthstone (ESTE) Likely to Beat Q4 Earnings Estimates?
by Zacks Equity Research
Earthstone Energy's (ESTE) fourth-quarter earnings are likely to have been aided by higher oil production.
Factors to Know Ahead of Talos Energy's (TALO) Q4 Earnings
by Zacks Equity Research
Talos Energy's (TALO) fourth-quarter earnings are expected to have taken a hit from lower realized commodity prices.
Why Alector (ALEC) Could Be Positioned for a Surge
by Zacks Equity Research
Alector (ALEC) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
4 Biotech Stocks That Could Keep Beating Wall Street
by Zacks Equity Research
The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.
AC Immune to Earn Milestone From Lilly for Alzheimer's Drug
by Zacks Equity Research
AC Immune (ACIU) will gain a milestone payment of CHF30 million from partner Eli Lilly for the initiation of the phase I study of ACI-3024, currently being developed to treat Alzheimer's disease.
6 Small Drug Stocks in Focus Ahead of World Alzheimer's Day
by Kinjel Shah
Here we discuss six small-cap companies with promising candidates in their pipeline for Alzheimer's disease.
AC Immune Initiates Phase I Study for Alzheimer's Disease
by Zacks Equity Research
AC Immune (ACIU) initiates phase I study of ACI-3024, a Tau Morphomer inhibitor, for the treatment of neurodegenerative diseases like Alzheimer's disease.
Alector (ALEC) Initiates Phase I Alzheimer's Study on AL003
by Zacks Equity Research
Alector, Inc. (ALEC) initiates the phase I INTERCEPT study on AL003 for the treatment of Alzheimer???s disease.